Clover Health Investments, Corp

Clover Health CEO Andrew Toy sold 313,476 shares worth $1.67 million on July 1, 2026, representing a 3.16% reduction in his direct holdings. The sale was a non-discretionary tax withholding event tied to RSU vesting, not a signal of lost confidence. Toy retains 9.6 million shares, maintaining significant alignment with shareholders. The sale come...

Clover Health board member Dr. Carladenise Armbrister Edwards sold 67,160 shares (~$230,000) on May 18, 2026, reducing her direct holdings by 19%. The sale occurred during muted stock performance, but the director has not sold additional shares despite the stock subsequently reaching a 52-week high of $5.49 following a favorable court ruling and ...

Conrad Wai, CEO of Clover Health's Counterpart Health subsidiary, sold 220,426 shares for approximately $879,000 on May 28, 2026. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as Wai retains over 2.5 million shares. The transaction occurred during a strong period for the company, with Q1 2026 showi...

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Healt...

The global insurtech market is projected to grow from $14 billion in 2026 to $638 billion by 2035, at a CAGR of 41.45%. Growth is driven by AI, blockchain, cloud computing, and machine learning technologies, with collaborations between traditional insurers and startups accelerating innovation. North America leads the market, while Asia is expecte...